Biologic discontinuation studies: a systematic review of methods
- 1 March 2014
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 73 (3) , 595-599
Abstract
Objectives We conducted a systematic review to assess the design and ‘failure definition’ in studies of biologic discontinuation in rheumatoid arthritis (RA). Methods We found 403 studies on PubMed, and included nine published papers and five abstracts from scientific meetings. We used a structured extraction form to collect information regarding study design and outcome (failure) definition. Results Three types of studies were found: randomised controlled trials, long-term extension studies of clinical trials and prospective discontinuation studies. The largest study had 196 subjects in the discontinuation arm. Most studies allowed concomitant use of non-biologic drugs at biologic discontinuation. Heterogeneity was also found in the failure definition. Although all studies used measures of disease activity, the threshold for failure and the time point of assessment differed among studies. Few studies incorporated changing use of non-biologic drugs or glucocorticoids into the failure definition. Conclusions Although many studies have examined the outcome of biologic discontinuation, they have all been relatively small. Typical practice studies from registries may add important information but will likely need to rely on a broader failure definition.Keywords
This publication has 14 references indexed in Scilit:
- Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated studyAnnals of the Rheumatic Diseases, 2013
- Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensusAnnals of the Rheumatic Diseases, 2012
- Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activityModern Rheumatology, 2012
- Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt studyAnnals of the Rheumatic Diseases, 2011
- Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) studyAnnals of the Rheumatic Diseases, 2010
- Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritisJoint Bone Spine, 2009
- Discontinuation of infliximab in rheumatoid arthritis patients in clinical remissionModern Rheumatology, 2008
- Discontinuation of infliximab in rheumatoid arthritis patients in clinical remissionModern Rheumatology, 2008
- Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable differenceArthritis & Rheumatism, 2002